For further details on collaborations within the SFB-F61, SFB-F47, ERA PerMed JAKSTAT-TARGET or ERANET-PLL network grants please follow the links.

National

Dr. Fritz Aberger, University Salzburg, Skin cancer and hedgehog/JAK-STAT crosstalk

Dr. Walter Berger,Medical University of Vienna, Translational cancer research and Comparative Genome Hybridization of patient-derived cancer cell lines

Dr. Michael Bergmann, Medical University Vienna, Colorectal cancer and chronic inflammatory gastrointestinal tract disease

Dr. Andreas Bergthaler, CeMM – Research Center for Molecular Medicine of the Austrian Academy of Sciences, Work on Tasmanian Devil Facial Tumor Disease and viral pathogenesis/antiviral immune responses

Dr. Christoph Bock, CeMM – Research Center for Molecular Medicine of the Austrian Academy of Sciences, Bioinformatics and gene expression analysis

Dr. Thomas Decker, Max Perutz Labs Vienna, STAT transcription factors in chromatin

Dr. Helmut Dolznig, Medical University Vienna, WNT signalling and colorectal cancer research

Dr. Florian Grebien, University of Veterinary Medicine, Vienna, Work on acute leukemias and targeting driver mutation products

Dr. Lukas Kenner, University of Veterinary Medicine, Vienna, Oncogenic STAT3/5 in prostate cancer and T cell neoplasms, histo-pathology and molecular pathology

Dr. Kristaps Klavins, CeMM – Research Center for Molecular Medicine of the Austrian Academy of Sciences, Metabolomics in T cell neoplasia

Dr. Heinrich Kovar, Children’s Cancer Research Institute Vienna, Sarcoma research and establishment of a mouse model for Ewing´s Sarcoma

Dr. Andrey Kozlov, Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Reactive Oxygen Species, liver damage and Nitric Oxide analyses

Dr. Robert Kralovics, CeMM – Research Center for Molecular Medicine of the Austrian Academy of Sciences, Myeloproliferative mouse models and JAK2V617F oncogene signalling

Dr. Stefan Kubicek, CeMM – Research Center for Molecular Medicine of the Austrian Academy of Sciences, Chemical screening, drug target identification and metabolomics

Dr. Grazyna Kwapiszewska / Dr. Leigh Marsh, Ludwig Boltzmann Institute for Lung Vascular Research, Lung vascular research and thromboembolism

Dr. Mario Mikula, Medical University Vienna, Melanoma research

Dr. Wolfgang Mikulits, Medical University Vienna, Liver cancer research

Dr. Mathias Müller, University of Veterinary Medicine, Vienna, TYK2 tyrosine kinase and transgenesis

Dr. Jan Michael Peters, Research Institute of Molecular Pathology, Higher order chromatin structures with STAT5 transcription factors

Dr. Thomas Rülicke, University of Veterinary Medicine, Vienna, Transgenesis and developing mouse models

Dr. Veronika Sexl, University of Veterinary Medicine, Vienna, JAK-STAT in cancer, acute leukemia resistance mechanisms and CDK6 kinase in cancer

Dr. Karl Sotlar, Uniklinikum Salzburg, Myeloproliferative neoplasm pathology

Dr. Birgit Strobl, University of Veterinary Medicine, Vienna, STAT1 transcription factor signalling

Dr. Peter Valent / Dr. Emir Hadzijusufovic, Medical University Vienna, Acute leukemias, thromboembolism and myeloproliferative neoplasms, targeting driver oncogenes

Dr. Peter Wolf, Department of Dermatology and Venereology, Medical University of Graz, Translational work on Cutaneous T cell Leukemia, Sezary syndrome and Mycosis Fungoides

International

Dr. Vasileios Bekiaris, Technical University of Denmark, Lyngby, Denmark, Role of STAT5 in T cell biology and autoimmune disease

Dr. Kevin D. Bunting, Emory University, Atlanta, USA, Interference with inhibitors of the PI3K-AKT-mTOR cascade and oncogenic STAT5 action in neoplastic cells

Dr. Stefan Constantinescu, Ludwig Cancer Institute, De Duve Institute, Brussels, Belgium, p53 mutations and interaction with STAT5 in myeloproliferative neoplasms and acute leukemias

Dr. Michael Deininger, Utah Huntsman CI, Salt Lake City, USA, STAT3/5 in the evolution, progression and targeting of chronic myeloid leukemia

Dr. Maria Fragiadaki, Academic Nephrology Unit, Department of Infection, Immunity and Cardiovascular Disease, The Medical School, University of Sheffield, Sheffield, England

Dr. Karlheinz Friedrich, Institute for Biochemistry, Friedrich Schiller University Jena, Jena, Germany, Colorectal cancer research

Dr. F. Gouilleux, Université Rabelais, Tours, France, STAT5 in leukemogenesis and PI3K-AKT-mTOR signaling, and proteolytic targeting of STAT5

Dr. Patrick T. Gunning / Dr. Elvin de Araujo, University of Toronto, Mississauga, Canada, Drug discovery based on key components of core cancer pathways

Dr. Xiaonan Han, Key Laboratory of Human Disease Comparative Medicine, Ministry of Health; the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing, China; Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children’s Hospital Medical Center (CCHMC), Cincinnati, Ohio, USA, STAT5 signaling in the gastrointestinal tract for inflammatory, infectious and neoplastic disease

Dr. Lothar Hennighausen, National Institutes of Health, Washington, USA, Immunity and cancer insights, mouse models of STAT5 function

Dr. Marco Herling, University of Cologne, Cologne, Germany, JAK-STAT signaling in T cell neoplasms and cancer cell metabolism

Dr. György M. Keserü, Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Budapest, Hungary, JAK-STAT inhibitors

Dr. Joe Lewis, European Molecular Biology Laboratory, Heidelberg, Germany, Chemical Biology Core Facility, Chemical biology

Dr. A. Thomas Look, Dana Farber, Boston, USA, T cell acute lymphoblastic leukemia, anaplastic large cell lymphoma and mutated JAK kinases

Dr. Satu Mustjoki, University of Helsinki, Helsinki, Finland, JAK-STAT signaling in mature T cell neoplasms

Dr. Gerhard Müller-Newen, Rheinisch-Westfälische Technische Hochschule Aachen, Germany, STAT5 shuttling in acute leukemias

Dr. John O’Shea, National Institutes of Health, Washington, USA, STAT5 function in T cells

Dr. Josef Prchal, University of Utah, USA, Myeloproliferative neoplasms and thrombosis research

Dr. William Tse, Metro Health Cancer Center, Case Western Reserve University, Ohio, USA, AF1q in carcinoma metastasis

Dr. Jan Tuckermann, University of Ulm, Ulm, Germany, Stress hormone receptor-STAT5 axis for metabolic control

Dr. K.U. Wagner, Wayne State University, Detroit, USA, JAK2-STAT5 signaling and transgenic mouse models